CGTX Latest Press Releases

-- October 22, 2026 --

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies Globe Newswire 6:00 AM

-- October 13, 2026 --

Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 Globe Newswire 6:00 AM

-- September 29, 2026 --

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB Globe Newswire 7:30 AM

-- September 8, 2026 --

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference Globe Newswire 7:30 AM

-- August 6, 2026 --

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update Globe Newswire 4:15 PM

-- July 13, 2026 --

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit Globe Newswire 7:30 AM

-- June 24, 2026 --

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes Globe Newswire 7:30 AM

-- June 16, 2026 --

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 Globe Newswire 7:30 AM

-- June 1, 2026 --

Cognition Therapeutics Participating in Upcoming Investor Conferences Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes